In breast cancer CD163+ CD14lowCD16+ and CD163+ CD14+CD16+ monocytes were indicative for the presence of the malignancy, and CD14lowCD16+HLA-DR + monocytes were predictive for the good response to neoadjuvant chemotherapy [156]. This evidence concerns the gene CD163 and breast carcinoma.